A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

237

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Healthy

Interventions

DRUG

Mirikizumab Prefilled Syringe

Administered SC by prefilled syringe

DRUG

Mirikizumab Autoinjector

Administered SC by autoinjector

Trial Locations (3)

LabCorp CRU, Inc., Daytona Beach

QPS, Springfield

Covance Dallas, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT05069896 - A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants | Biotech Hunter | Biotech Hunter